BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Closed Martin Luther King, Jr. Day 01-16 16:00:00 EST

338.19

-0.10

-0.03%

盘后338.19

+0.000.00%

19:14 EST

High340.83	Low336.18	Vol153.66K
Open338.07	D1 Closing338.29	Amplitude1.37%
Mkt Cap40.24B	Tradable Cap25.58B	Total Shares119.00M
T/O52.04M	T/O Rate0.20%	Tradable Shares75.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":338.19,"timestamp":1768597200000,"preClose":338.29,"halted":0,"volume":153657,"hourTrading":{"tag":"盘后","latestPrice":338.19,"preClose":338.19,"latestTime":"19:14 EST","volume":1376,"amount":465355.63,"timestamp":1768608897924,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00029560436312046684,"floatShares":75641900,"shares":119000000,"eps":0.584711,"marketStatus":"Closed Martin Luther King, Jr. Day","change":-0.1,"latestTime":"01-16 16:00:00 EST","open":338.07,"high":340.83,"low":336.18,"amount":52044345.01476,"amplitude":0.013746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.584711,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":338.29,"preHourTrading":{"tag":"盘前","latestPrice":337.02,"preClose":338.29,"latestTime":"08:04 EST","volume":19,"amount":6397.25972,"timestamp":1768568648417,"change":-1.27,"changeRate":-0.003754,"amplitude":0.001005},"postHourTrading":{"tag":"盘后","latestPrice":338.19,"preClose":338.19,"latestTime":"19:14 EST","volume":1376,"amount":465355.63,"timestamp":1768608897924,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.38098461285836116,"impliedVol":0.344,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ONC/wiki","defaultTab":"wiki","newsList":[{"id":"1168374108","title":"CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1168374108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168374108?lang=en_us&edition=fundamental","pubTime":"2026-01-19 14:24","pubTimestamp":1768803841,"startTime":"0","endTime":"0","summary":"According to a research report from CICC, Hang Seng Indexes Company will announce the official results of the Hang Seng Index Series review after the market close on Friday, February 13, 2026, with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1198","LU2213484517.USD","MCHmain","02833","HHImain","06181","09868","YUMC","02259","SGXZ62798434.SGD","06160","LU0593848301.USD","HK0000252160.HKD","688235","09926","02328","HK0000500386.USD","513600","SGXZ86797644.SGD","LU2543165471.USD","XPEV","02601","09987","ONC","BK4614","601601","HK0000252152.HKD"],"gpt_icon":1},{"id":"2603050601","title":"Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603050601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603050601?lang=en_us&edition=fundamental","pubTime":"2026-01-15 19:36","pubTimestamp":1768476990,"startTime":"0","endTime":"0","summary":"In a report released on January 13, Yigal Nochomovitz from Citi maintained a Buy rating on BeOne Medicines, with a price target of $405.00. The com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-their-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-their-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","ONC"],"gpt_icon":0},{"id":"2603604820","title":"HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603604820","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603604820?lang=en_us&edition=fundamental","pubTime":"2026-01-15 16:23","pubTimestamp":1768465435,"startTime":"0","endTime":"0","summary":"BeOne Medicines recently presented full Phase 3 HERIZON-GEA-01 results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2-positive gastroesophageal adenocarcinoma at the 2026 ASCO GI Cancers Symposium in San Francisco, including an interim overall survival analysis.\nThe regimen’s high overall response rate and prolonged median duration of response, combined with BeOne’s commercial rights to ZIIHERA across much of Asia Pacific, elevate the potential...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/herizon-gea-01-phase-3-zanidatamab-combo-data-might-change-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/herizon-gea-01-phase-3-zanidatamab-combo-data-might-change-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4585","BK4526","BK4139","MDCO"],"gpt_icon":0},{"id":"1124618498","title":"Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=1124618498","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124618498?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:34","pubTimestamp":1768354465,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million. On January 14, the company announced via its official WeChat...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","LU0307460666.USD","LU1719994722.HKD","BK0239","LU1303224171.USD","LU2328871848.SGD","688235","06160","BK4139","BK1500","BK4526","LU1770034418.SGD","BK4585","BK1161","LU0588546209.SGD","LU1251922891.USD","BK1583","LU1969619763.USD","BK1588"],"gpt_icon":0},{"id":"2602519915","title":"Beone Medicines : Bernstein Raises to Outperform From Market-Perform; Raises Target Price to $414 From $362","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602519915?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:19","pubTimestamp":1768216792,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4526","BK4139","ONC","688235","BK0239"],"gpt_icon":0},{"id":"2601656233","title":"Beone Medicines : RBC Raises Target Price to $417 From $408","url":"https://stock-news.laohu8.com/highlight/detail?id=2601656233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601656233?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:30","pubTimestamp":1767871812,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688235","BK4526","ONC","BK4139","BK4585","BK0239"],"gpt_icon":0},{"id":"2601383883","title":"Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383883","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383883?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:12","pubTimestamp":1767809520,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PFS","BK4097","BK4526","IE00B7SZL793.SGD","ONC","LU1815336091.USD","BK4533","LU0109394709.USD","BK4195","IE00B66KJ199.SGD","BK4157","LU0823416689.USD","IE00B19Z4B17.USD","LU0889565916.HKD","BK4139","LU0154245756.USD","LU0320765992.SGD","OS","BK4532","AEIS","LU0757428866.USD","IE00BN0W2V16.EUR","ZYME","BK4211","BK4007","BK4585","LU0154245673.USD","JAZZ","IE00BN0W2T93.GBP","IE0031619046.USD","IE00BN0W2W23.USD"],"gpt_icon":0},{"id":"1131095987","title":"BEIGENE (06160) Awards Total of 53,300 Restricted Stock Units in American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1131095987","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131095987?lang=en_us&edition=fundamental","pubTime":"2026-01-07 16:54","pubTimestamp":1767776058,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on December 31, 2025, the Board of Directors and/or the Board's Remuneration Committee granted a total of 53,300 restricted stock units in the form of American...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","LU0588546209.SGD","LU0307460666.USD","LU1969619763.USD","688235","BK4139","06160","BK4526","BK1588","BK1500","BK0239","BK1161","LU1251922891.USD","LU1303224171.USD","BK1583","LU1770034418.SGD","LU2328871848.SGD","BK4585","LU1719994722.HKD"],"gpt_icon":0},{"id":"1105381988","title":"BEIGENE's BCL-2 Inhibitor \"Sotokela\" Approved for Market Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1105381988","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105381988?lang=en_us&edition=fundamental","pubTime":"2026-01-05 18:40","pubTimestamp":1767609636,"startTime":"0","endTime":"0","summary":"On January 5th, the NMPA official website indicated that BEIGENE's BCL-2 inhibitor \"Sotokela\" has received approval in China for two indications. It is indicated for the treatment of adult patients...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","LU1251922891.USD","LU2328871848.SGD","BK1161","LU1719994722.HKD","BK0239","06160","LU1969619763.USD","LU0307460666.USD","BK4585","BK4139","LU0588546209.SGD","BK1588","ONC","LU1770034418.SGD","BK1500","LU1303224171.USD","688235","BK1583"],"gpt_icon":0},{"id":"2592890869","title":"BeOne Medicines Says US FDA's Fast Track Designation Received for Hepatocellular Carcinoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2592890869","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592890869?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:57","pubTimestamp":1766059025,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Thursday its BGB-B2033 antibody has received the US Food and Drug Administration's Fast Track Designation to treat adult patients with hepatocellular carcinoma.The company is currently carrying out a phase 1 clinical study to evaluate the safety and anti-tumor activity of BGB-B2033, BeOne Medicines said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","BK4526","BK4139","MDCO","BK4585"],"gpt_icon":0},{"id":"1174588607","title":"Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE","url":"https://stock-news.laohu8.com/highlight/detail?id=1174588607","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174588607?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:40","pubTimestamp":1765777238,"startTime":"0","endTime":"0","summary":"On the afternoon of December 15, the Hong Kong Stock Connect innovative drug sector accelerated its decline, with the HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880)...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU0417516902.SGD","LU0348767384.USD","LU0417516571.SGD","LU1251922891.USD","LU0348766576.USD","BK0239","LU2778985437.USD","LU1303224171.USD","BK4526","LU0561508036.HKD","520880","BK1574","LU2476274720.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU1719994722.HKD","LU1720050803.USD","LU1770034418.SGD","LU0307460666.USD","BK1588","BK1500","LU0417516738.SGD","LU2476274308.USD","LU2328871848.SGD","IE00B543WZ88.USD","ONC","LU0540923850.HKD","LU0348827113.USD","688235","BK4585","LU0348784397.USD","BK1161","LU2488822045.USD","06160","LU0348735423.USD","BK4139","LU1961090484.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","LU1794554557.SGD","LU1969619763.USD","LU0348825331.USD","09926","LU0634319403.HKD","BK1583"],"gpt_icon":0},{"id":"2590444539","title":"BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590444539","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590444539?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:31","pubTimestamp":1765384283,"startTime":"0","endTime":"0","summary":"BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK4585","BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2589090158","title":"BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features","url":"https://stock-news.laohu8.com/highlight/detail?id=2589090158","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589090158?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:03","pubTimestamp":1765148580,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49248671/beone-medicines-announced-sonrotoclax-in-combination-with-brukinsa-demonstrated-rapid-mrd-negativity","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49248671/beone-medicines-announced-sonrotoclax-in-combination-with-brukinsa-demonstrated-rapid-mrd-negativity","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2463526074.USD","MDCO","ONC","ASH","BK4526","BK4139","BK4109","BK4585"],"gpt_icon":0},{"id":"1102399328","title":"BEIGENE (06160) Grants a Total of 21,300 Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1102399328","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102399328?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:00","pubTimestamp":1764838818,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on November 28, 2025, the Board's Compensation Committee granted a total of 21,300 restricted share units (RSUs) in the form of American Depositary Shares (ADSs) to 147...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK1588","688235","LU2328871848.SGD","BK4585","LU1770034418.SGD","ONC","BK4139","BK0239","LU0307460666.USD","BK1500","LU1251922891.USD","06160","LU1969619763.USD","LU1303224171.USD","BK1583","BK1161","LU1719994722.HKD","LU0588546209.SGD"],"gpt_icon":0},{"id":"2586574212","title":"Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Key Economic Data Deluge","url":"https://stock-news.laohu8.com/highlight/detail?id=2586574212","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586574212?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:29","pubTimestamp":1764163749,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% higher in Wednesday's premarket activity as investors await a de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BETH","UNG","RTH","VIS","XLP","EEM","IGV","IVV","SPY","XSD","ONC","BITO","RTH.AU","VDC","IPK","XRT","SUPV","SOXX","USO","VHT.AU","XLE","XLI","PMR","XLK",".DJI","XLY","XLV","IGM","FAS","FAZ","XLF","EETH","IYW","IBB","SLV","UBER","VHT","EXI","EQR","IYE","SPY.AU","IYH","DE","IYK","IYJ"],"gpt_icon":1},{"id":"2586250534","title":"BeOne Medicines (ONC): Assessing Valuation Following Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250534?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:37","pubTimestamp":1764160626,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) has been getting attention for its recent stock performance, with shares showing noticeable movement over the past month. Investors are keeping an eye on how the company’s sustained gains might reflect its current direction.\nSee our latest analysis for BeOne Medicines.\nThe stock’s 6.3% share price return over the past month signals growing momentum and builds on the impressive 82% year-to-date gain. While short-term pullbacks have occurred, BeOne Medicines stands out due...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-assessing-valuation-following-recent-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-assessing-valuation-following-recent-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4526","BK4139","MDCO","BK4585"],"gpt_icon":0},{"id":"2586725679","title":"BeOne Medicines Lymphoma Drug Gets FDA Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2586725679","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586725679?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:21","pubTimestamp":1764156060,"startTime":"0","endTime":"0","summary":"BeOne Medicines said U.S. regulators have agreed to fast-track the review its new drug to treat adults with mantle cell lymphoma, a form of blood cancer.The cancer treatment company said Wednesday that the Food and Drug Administration has accepted and granted priority review to a new drug application for sonrotoclax, a new BCL2 inhibitor intended to treat adult patients with relapsed or refractory mantle cell lymphoma.Mantle cell lymphoma is a rare, fast-growing blood cancer that starts in the lymph nodes.The decision was based on data from a phase 1/2 study which enrolled 125 adult patients with the specific type of blood cancer who had received prior treatment. The trial results found that sonorotoclax achieved its primary endpoints of overall response rate, and also showed promising results across several secondary efficacy endpoints, it said.\"Sonrotoclax is advancing with remarkable speed, from breakthrough therapy designation to priority review, all within a short window,\" Global ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4526","MDCO","BK4139","BK4585"],"gpt_icon":0},{"id":"2586256118","title":"BeOne Medicines says FDA grants Priority Review to NDA for sonrotoclax","url":"https://stock-news.laohu8.com/highlight/detail?id=2586256118","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586256118?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:05","pubTimestamp":1764155134,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has accepted and granted Priority Review to a New Drug Application for sonrotoclax, a next-genera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-says-fda-grants-priority-review-to-nda-for-sonrotoclax-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-says-fda-grants-priority-review-to-nda-for-sonrotoclax-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4526","BK4139","BK4585","MDCO"],"gpt_icon":0},{"id":"2586476871","title":"Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476871?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:36","pubTimestamp":1764077793,"startTime":"0","endTime":"0","summary":"In a report released today, Clara Dong from Jefferies maintained a Buy rating on BeOne Medicines, with a price target of $420.00. According to TipR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2586427711","title":"BeOne Medicines (ONC) Is Up After ZIIHERA Phase 3 Trial Shows Strong Efficacy for HER2-Positive Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586427711","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586427711?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:22","pubTimestamp":1764069734,"startTime":"0","endTime":"0","summary":"In November 2025, BeOne Medicines Ltd. announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial, showing that ZIIHERA (zanidatamab) in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA, led to highly statistically significant improvements in progression-free and overall survival for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.\nThe study’s results highlight both clinically meaningful efficacy benefits and a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-is-up-after-ziihera-phase-3-trial-shows","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-is-up-after-ziihera-phase-3-trial-shows","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","MDCO","BK4526","BK4139","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":0.105},{"period":"3month","weight":0.0688},{"period":"6month","weight":0.1482},{"period":"1year","weight":0.647},{"period":"ytd","weight":0.1132}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.082988},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction